New hope for advanced blood cancers: experimental drug EP0042 enters human testing

NCT ID NCT04581512

Recruiting now Disease control Sponsor: Ellipses Pharma Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new experimental drug called EP0042 in adults with advanced acute myeloid leukemia (AML) or related blood cancers. The goal is to find a safe dose that might work against the cancer, either alone or with other treatments. About 70 participants will take part to check for side effects and see how the drug behaves in the body.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia chronic myelomonocytic leukemia myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA CHRONIC MYELOMONOCYTIC LEUKEMIA MYELODYSPLASTIC SYNDROMES

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Amsterdam UMC
RECRUITING

Amsterdam, 1081HV Amsterdam, Netherlands
Erasmus MC
RECRUITING

Rotterdam, 3000 CA Rotterdam, Netherlands
Royal Perth Hospital
RECRUITING

Perth, Western Australia, 6000, Australia
The Christie Hospital
RECRUITING

Manchester, M204BX, United Kingdom
The Royal Marsden
RECRUITING

London, UK, United Kingdom
University College London Hospital
RECRUITING

London, W1T 7HA, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.